Yanyan Chen1,2, Hongmei Jia3, Xin Qian1, Jinping Wang4, Meng Yu3, Qiuhong Gong1, Yali An1, Hui Li4, Sidong Li5, Na Shi1, Zhongmei Zou3, Guangwei Li1,6. 1. Endocrinology Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Endocrinology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen, Guangdong, China. 3. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 4. Department of Cardiology, Da Qing First Hospital, Da Qing, China. 5. Medical Research and Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. 6. Department of Endocrinology, China-Japan Friendship Hospital, Beijing.
Abstract
OBJECTIVE: To investigate the association of potential cardiovascular disease (CVD) biomarkers in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We enrolled 120 participants (aged 61.5-69.5 years) with type 2 diabetes and 60 (aged 62.5-73.5 years) with normal glucose tolerance in the discovery group from the original Da Qing Diabetes Study. Their diabetes status was confirmed in 1986; then, the participants were followed over 23 years to collect CVD outcome data. Untargeted and targeted metabolomics analyses based on ultra-high-performance liquid chromatography-tandem mass spectrometry were used to identify potential markers. Multivariable regression analysis was used to evaluate the association between metabolites and CVD outcomes. An independent group of 335 patients (aged 67.0-77.0 years) with diabetes was used for biomarker validation. RESULTS: In the discovery group, untargeted metabolomics analysis found 16 lipids and fatty acids metabolites associated with CVD risk in patients with diabetes, with palmitoyl sphingomyelin (PSM) having the strongest association. Plasma PSM concentrations were significantly higher in cases of diabetes with CVD than without (41.68 ± 10.47 vs. 9.69 ± 1.47 μg/mL; P < 0.0001). The odds ratio (OR) of CVD for 1 µg/mL PSM change was 1.19 (95% CI 1.13-1.25) after adjustment of clinical confounders. The validation study confirmed that PSM was significantly associated with increased CVD risk in diabetes (OR 1.22 [95% CI 1.16-1.30]). CONCLUSIONS: Changes in lipid and fatty acid content were significantly associated with CVD risk in the Chinese population with diabetes. PSM is a potential biomarker of increased CVD risk in diabetes.
OBJECTIVE: To investigate the association of potential cardiovascular disease (CVD) biomarkers in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: We enrolled 120 participants (aged 61.5-69.5 years) with type 2 diabetes and 60 (aged 62.5-73.5 years) with normal glucose tolerance in the discovery group from the original Da Qing Diabetes Study. Their diabetes status was confirmed in 1986; then, the participants were followed over 23 years to collect CVD outcome data. Untargeted and targeted metabolomics analyses based on ultra-high-performance liquid chromatography-tandem mass spectrometry were used to identify potential markers. Multivariable regression analysis was used to evaluate the association between metabolites and CVD outcomes. An independent group of 335 patients (aged 67.0-77.0 years) with diabetes was used for biomarker validation. RESULTS: In the discovery group, untargeted metabolomics analysis found 16 lipids and fatty acids metabolites associated with CVD risk in patients with diabetes, with palmitoyl sphingomyelin (PSM) having the strongest association. Plasma PSM concentrations were significantly higher in cases of diabetes with CVD than without (41.68 ± 10.47 vs. 9.69 ± 1.47 μg/mL; P < 0.0001). The odds ratio (OR) of CVD for 1 µg/mL PSM change was 1.19 (95% CI 1.13-1.25) after adjustment of clinical confounders. The validation study confirmed that PSM was significantly associated with increased CVD risk in diabetes (OR 1.22 [95% CI 1.16-1.30]). CONCLUSIONS: Changes in lipid and fatty acid content were significantly associated with CVD risk in the Chinese population with diabetes. PSM is a potential biomarker of increased CVD risk in diabetes.
Authors: Geoffrey A Walford; Jaclyn Davis; A Sofia Warner; Rachel J Ackerman; Liana K Billings; Bindu Chamarthi; Rebecca R Fanelli; Alicia M Hernandez; Chunmei Huang; Sabina Q Khan; Katherine R Littleton; Janet Lo; Rita M McCarthy; Eugene P Rhee; Amy Deik; Elliot Stolerman; Andrew Taylor; Margo S Hudson; Thomas J Wang; David Altshuler; Richard W Grant; Clary B Clish; Robert E Gerszten; Jose C Florez Journal: Metabolism Date: 2013-08-15 Impact factor: 8.694
Authors: X C Jiang; F Paultre; T A Pearson; R G Reed; C K Francis; M Lin; L Berglund; A R Tall Journal: Arterioscler Thromb Vasc Biol Date: 2000-12 Impact factor: 8.311
Authors: Marta Guasch-Ferré; Adela Hruby; Estefanía Toledo; Clary B Clish; Miguel A Martínez-González; Jordi Salas-Salvadó; Frank B Hu Journal: Diabetes Care Date: 2016-05 Impact factor: 19.112
Authors: Peter W G Tennant; Eleanor J Murray; Kellyn F Arnold; Laurie Berrie; Matthew P Fox; Sarah C Gadd; Wendy J Harrison; Claire Keeble; Lynsie R Ranker; Johannes Textor; Georgia D Tomova; Mark S Gilthorpe; George T H Ellison Journal: Int J Epidemiol Date: 2021-05-17 Impact factor: 7.196
Authors: Yali An; Ping Zhang; Jinping Wang; Qiuhong Gong; Edward W Gregg; Wenying Yang; Hui Li; Bo Zhang; Ying Shuai; Yanyan Chen; Michael M Engelgau; Yiling Cheng; Yinghua Hu; Peter H Bennett; Guangwei Li Journal: Diabetes Care Date: 2015-04-17 Impact factor: 19.112
Authors: Luis F Ferreira-Divino; Tommi Suvitaival; Cristina Legido-Quigley; Peter Rossing; Viktor Rotbain Curovic; Nete Tofte; Kajetan Trošt; Ismo M Mattila; Simone Theilade; Signe A Winther; Tine W Hansen; Marie Frimodt-Møller Journal: Cardiovasc Diabetol Date: 2022-07-18 Impact factor: 8.949
Authors: Paul N Jensen; Amanda M Fretts; Andrew N Hoofnagle; Barbara McKnight; Barbara V Howard; Jason G Umans; Colleen M Sitlani; David S Siscovick; Irena B King; Nona Sotoodehnia; Rozenn N Lemaitre Journal: Cardiovasc Diabetol Date: 2022-08-30 Impact factor: 8.949